FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2645606857> ?p ?o ?g. }

• W2645606857 endingPage "315" @default.
• W2645606857 startingPage "307" @default.
• W2645606857 abstract "We investigated the efficacy and safety of 60, 120, or 240 mg of Z-360, which is a highly potent cholecystokinin2-receptor-selective antagonist, combined with gemcitabine in patients with metastatic pancreatic cancer.Patients were randomly assigned in a 1:1:1:1 ratio to one of four treatment groups. Patients received 1000 mg/m2 gemcitabine for each cycle and Z-360 tablets of 60 mg (GZ 60 mg group), 120, 240 mg or placebo tablets (Gem group) orally twice daily. The primary endpoint was overall survival (OS).The median OS was 1.3 months longer in the GZ 60 mg group compared with the Gem group (8.5 vs. 7.2 months) and the risk of death was reduced by 19% compared with the Gem group, although there were no statistically significant differences. The study treatments were well tolerated.In this Phase II study, no statistically significant differences between the GZ groups and Gem group were detected in any analysis. However, Z-360 in dose of 60 mg tends to improve OS in patients with metastatic pancreatic cancer with low toxic effect. Further exploratory trials with other agents such as gemcitabine plus nab-paclitaxel might be beneficial." @default.
• W2645606857 created "2017-06-30" @default.
• W2645606857 creator A5005933314 @default.
• W2645606857 creator A5008014743 @default.
• W2645606857 creator A5014734397 @default.
• W2645606857 creator A5015703802 @default.
• W2645606857 creator A5022537134 @default.
• W2645606857 creator A5023824371 @default.
• W2645606857 creator A5026988448 @default.
• W2645606857 creator A5042323474 @default.
• W2645606857 creator A5050530209 @default.
• W2645606857 creator A5056197140 @default.
• W2645606857 creator A5057311746 @default.
• W2645606857 creator A5065581439 @default.
• W2645606857 creator A5066857172 @default.
• W2645606857 creator A5068601802 @default.
• W2645606857 creator A5076696174 @default.
• W2645606857 date "2017-06-20" @default.
• W2645606857 modified "2023-10-16" @default.
• W2645606857 title "A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo" @default.
• W2645606857 cites W2034311601 @default.
• W2645606857 cites W2045390516 @default.
• W2645606857 cites W2054888873 @default.
• W2645606857 cites W2106787323 @default.
• W2645606857 cites W2124604698 @default.
• W2645606857 cites W2133364214 @default.
• W2645606857 cites W2151253787 @default.
• W2645606857 cites W2160476292 @default.
• W2645606857 cites W2165480504 @default.
• W2645606857 cites W2267156748 @default.
• W2645606857 cites W2324457843 @default.
• W2645606857 doi "https://doi.org/10.1007/s00280-017-3351-4" @default.
• W2645606857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5532401" @default.
• W2645606857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28634650" @default.
• W2645606857 hasPublicationYear "2017" @default.
• W2645606857 type Work @default.
• W2645606857 sameAs 2645606857 @default.
• W2645606857 citedByCount "9" @default.
• W2645606857 countsByYear W26456068572018 @default.
• W2645606857 countsByYear W26456068572020 @default.
• W2645606857 countsByYear W26456068572021 @default.
• W2645606857 countsByYear W26456068572022 @default.
• W2645606857 countsByYear W26456068572023 @default.
• W2645606857 crossrefType "journal-article" @default.
• W2645606857 hasAuthorship W2645606857A5005933314 @default.
• W2645606857 hasAuthorship W2645606857A5008014743 @default.
• W2645606857 hasAuthorship W2645606857A5014734397 @default.
• W2645606857 hasAuthorship W2645606857A5015703802 @default.
• W2645606857 hasAuthorship W2645606857A5022537134 @default.
• W2645606857 hasAuthorship W2645606857A5023824371 @default.
• W2645606857 hasAuthorship W2645606857A5026988448 @default.
• W2645606857 hasAuthorship W2645606857A5042323474 @default.
• W2645606857 hasAuthorship W2645606857A5050530209 @default.
• W2645606857 hasAuthorship W2645606857A5056197140 @default.
• W2645606857 hasAuthorship W2645606857A5057311746 @default.
• W2645606857 hasAuthorship W2645606857A5065581439 @default.
• W2645606857 hasAuthorship W2645606857A5066857172 @default.
• W2645606857 hasAuthorship W2645606857A5068601802 @default.
• W2645606857 hasAuthorship W2645606857A5076696174 @default.
• W2645606857 hasBestOaLocation W26456068571 @default.
• W2645606857 hasConcept C121608353 @default.
• W2645606857 hasConcept C126322002 @default.
• W2645606857 hasConcept C142724271 @default.
• W2645606857 hasConcept C143998085 @default.
• W2645606857 hasConcept C168563851 @default.
• W2645606857 hasConcept C170493617 @default.
• W2645606857 hasConcept C203092338 @default.
• W2645606857 hasConcept C204787440 @default.
• W2645606857 hasConcept C27081682 @default.
• W2645606857 hasConcept C2776694085 @default.
• W2645606857 hasConcept C2776885963 @default.
• W2645606857 hasConcept C2777844706 @default.
• W2645606857 hasConcept C2780210213 @default.
• W2645606857 hasConcept C2780258809 @default.
• W2645606857 hasConcept C31760486 @default.
• W2645606857 hasConcept C71924100 @default.
• W2645606857 hasConcept C90924648 @default.
• W2645606857 hasConceptScore W2645606857C121608353 @default.
• W2645606857 hasConceptScore W2645606857C126322002 @default.
• W2645606857 hasConceptScore W2645606857C142724271 @default.
• W2645606857 hasConceptScore W2645606857C143998085 @default.
• W2645606857 hasConceptScore W2645606857C168563851 @default.
• W2645606857 hasConceptScore W2645606857C170493617 @default.
• W2645606857 hasConceptScore W2645606857C203092338 @default.
• W2645606857 hasConceptScore W2645606857C204787440 @default.
• W2645606857 hasConceptScore W2645606857C27081682 @default.
• W2645606857 hasConceptScore W2645606857C2776694085 @default.
• W2645606857 hasConceptScore W2645606857C2776885963 @default.
• W2645606857 hasConceptScore W2645606857C2777844706 @default.
• W2645606857 hasConceptScore W2645606857C2780210213 @default.
• W2645606857 hasConceptScore W2645606857C2780258809 @default.
• W2645606857 hasConceptScore W2645606857C31760486 @default.
• W2645606857 hasConceptScore W2645606857C71924100 @default.
• W2645606857 hasConceptScore W2645606857C90924648 @default.
• W2645606857 hasIssue "2" @default.
• W2645606857 hasLocation W26456068571 @default.
• W2645606857 hasLocation W26456068572 @default.
• W2645606857 hasLocation W26456068573 @default.

• next